ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2020 - 2026)
ADC Therapeutics (ADCT) posted Net Income towards Common Stockholders of -$33.0 million for Q1 2026, up 19.52% sequentially from -$41.0 million in Q3 2025, and up 14.6% YoY from -$28.8 million in Q1 2025.
ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$33.0 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.6% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.6 million (down 10.42% YoY) and the FY2022 annual result came in at -$152.6 million, up 33.84% from the prior year.
- Net Income towards Common Stockholders climbed to -$33.0 million in Q1 2026 per ADCT's latest filing, from -$41.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$16.7 million in Q1 2022 and troughed at -$64.4 million in Q2 2022.
- A 5-year average of -$42.7 million and a median of -$44.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders soared 67.67% in 2022, then sank 256.68% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$18.2 million in 2022, then sank by 149.56% to -$45.3 million in 2023, then rose by 3.52% to -$43.7 million in 2024, then advanced by 6.28% to -$41.0 million in 2025, then rose by 19.52% to -$33.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$33.0 million, -$41.0 million, and -$56.6 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.57 Mn |
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -56.65 Mn |
| Mar 31, 2025 | -38.60 Mn |
| Sep 30, 2024 | -43.71 Mn |
| Jun 30, 2024 | -35.95 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Sep 30, 2023 | -45.30 Mn |
| Jun 30, 2023 | -48.20 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -50.61 Mn |
| Jun 30, 2022 | -64.37 Mn |
| Mar 31, 2022 | -16.66 Mn |
| Dec 31, 2021 | -35.52 Mn |
| Sep 30, 2021 | -71.55 Mn |
| Jun 30, 2021 | -72.57 Mn |
| Mar 31, 2021 | -51.53 Mn |
| Dec 31, 2020 | -56.26 Mn |